Callitas Health Inc. (fka MPHMF)

[Renee]

MPHMF: inactive security. FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Greta Grabo]

$LILY: CSE / MPHMF

Callitas Health, Inc. Releases End-of-Year Update Letter to Shareholders

CINCINNATI, OH, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (LILY: CSE | OTCQB: MPHMF | FWB: T3F3), today announced that President and Chief Executive Officer, James Thompson, has issued the following letter to shareholders. Read More. and for complete information: https://callitas.com/

[Greta Grabo]

$LILY / $MPHMF
The Medical Marijuana Revolution CALLITAS HEALTH INC: Explosive Ground-Breaking Products



Orlistat C - 103 - Weight Loss

ToConceive - Fertility Enhancing Moisturizer

Extrinsic - Female Sexual Dysfunction Solution
CannaMint Strips Callitas to position itself in the cannabinoids market. “

For More Product Information: https://callitas.com/our-products/

[Greta Grabo]

$LILY: CSE | $MPHMF

Undervalued Medical Marijuana Company Time to Buy!
Callitas Health, Inc. (OTCQB: MPHMF | CSE: LILY | FSE: T3F3) an integrated clinical-stage pharmaceutical development, OTC consumer goods company focusing on targeting cannabinoid delivery products and other proprietary drugs in the area of weight management, female sexual health/wellness and female reproduction. Read More Now! http://www.thestreetnow.com/spotlight/mphmf/

[Greta Grabo]

$LILY.V / $MPHMF - The Medical Marijuana Revolution



Ground-Breaking Drug Treatments and Biomedical Technologies


Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F3) has targeted cannabinoid delivery products and other proprietary drugs and technologies for weight management, female sexual health and the cannabis delivery. These ground-breaking drug treatments and biomedical technologies, including but not limited to C-103, ToConceive, Extrinsa and CannaMintStrips. Read More.

[traderdogzz]

Callitas Health, Inc. (OTCQB: MPHMF | CSE: LILY | FSE: T3F3) - Closed Up 14.29% in Canada -- UnderValued – 52 Week High $0.40 CAD and $0.284 USD - Optimal Entry Point Now!
http://www.thestreetnow.com/spotlight/mphmf/

[traderdogzz]

$MPHMF AWESOME COMPANY VIDEO...

[traderdogzz]

$MPHMF
Callitas Health, Inc. (OTCQB: MPHMF | CSE: LILY | FSE: T3F3) an integrated clinical-stage pharmaceutical development, OTC consumer goods company focusing on targeting cannabinoid delivery products and other proprietary drugs in the area of weight management, female sexual health/wellness and female reproduction.

http://www.thestreetnow.com/spotlight/marijuana-stock-alerts/

[White Shadow]

Taking too long!!!

[traderdogzz]

"Callitas Health Inc is a clinical-stage company engaged in developing technologies for obesity, weight management and female health & wellness. Its products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa."

[traderdogzz]

$MPHMF word is CEo moving the company forward now. Doing DD now on this company.

[traderdogzz]

https://callitas.com/

[traderdogzz]

Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the ”Company” or ”Callitas”) an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that it signed a definitive Patent Technology Assignment Agreement with Ronald J. Thompson, MD to expand its cannabis delivery technology portfolio. The new intellectual property acquired (four separate patent applications) will cover various novel oral and ingestible products including those for orally dissolving immediate cannabis effect, sustained release cannabis effect, and a combination of both. It will also cover products for the appropriate individual controlled dosing of CBD and/or THC for the legal, adult use and medical marijuana markets.

[Greta Grabo]

$MPHMF / $LILY:CSE

Callitas Health Signs Dr. Gregory Smith MD, MPH, as the Company's Chief Medical Cannabis Advisor
CINCINNATI, OH, May 21, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE:LILY) (OTCQB:MPHMF) (FWB:T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced today that it has signed industry expert Dr. Gregory Smith MD, MPH, as the Company’s Chief Medical Cannabis Advisor. The addition of Dr. Smith will help give the Company additional product development, clinical study capabilities and visibility in the THC/CBD (cannabinoids) market. For More Information http://www.thestreetnow.com/spotlight/mphmf/ ..

[NYOptionsGuy]

Callitas Signs Dr. Gregory Smith as the Chief Medical Cannabis Advisor

SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/05/21/LILY-MPHMF-Callitas-Signs-Dr-Gregory-Smith-as-the-Chief-Medical-Cannabis-Advisor

CINCINNATI, OH, May 21, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE:LILY) (OTC:MPHMF) (FWB:T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced today that it has signed industry expert Dr. Gregory Smith MD, MPH, as the Company’s Chief Medical Cannabis Advisor. The addition of Dr. Smith will help give the Company additional product development, clinical study capabilities and visibility in the THC/CBD (cannabinoids) market.



“We believe the addition of Dr. Smith to the Callitas team will help us better navigate the quickly evolving cannabinoid industry and provide expert insight for our current products and future programs in research and development,” said James Thompson, Interim President and CEO. “He brings a wealth of knowledge, clinical experience and insights that will be invaluable for our Company’s growth.”



After receiving his medical degree from Rush Medical School in Chicago, Dr. Smith went on to earn a Masters of Public Health degree from Harvard University. Since leaving the U.S. Army as a Major, Dr. Smith worked in primary care practice in California, Georgia and Florida for the past 30 years. He first trained on use of medical cannabis in California in 2000, and subsequently, has published over a dozen peer-reviewed medical publications, two medical textbooks and “CBD (Cannabidiol) What You Need to Know”.



Dr. Smith has garnered extensive experience and education in the field of cannabinoid medication, and currently serves as the editor-in-chief of www.Cannabis-MD.com, and Director of Medical Affairs for First Harvest Financial, Inc. (a cannabis investment firm).



“I’ve been working with medical cannabis-related products for the last four years and am very excited to see what Callitas has in the pipeline,” said Dr. Smith. “The team at Callitas is focused on putting innovative technologies on the market, and I’m looking forward to helping Callitas bring these current and new projects to fruition, quickly and with best medical practices.”



About Callitas Health: Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive (www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.



Notice regarding Forward Looking Statements:This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.



Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.



Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.

[White Shadow]

What is going on with this stock?? I'm very very disappointed! !

[tschoi]

Same for me - maybe later.
There is potential behind this c. Maybe they find a partner soon...
Glta

[Chaka]

I'm still eyeing from afar my friend.
Extrinsa is a huge market $$$ for sure.
I think the PPS will continues to drop further before some major event taking place.
I will re-enter MPHMF @ a later time.
Maybe.
glta.

[tschoi]

Great news about Extrinsa!!

Extrinsa

[Chaka]

This stock is so DISAPPOINTING tbh.
The delay in July + RS + more delay?
I understand unforeseen happen.
But, still..
I will give another 4-8 weeks..
If nothing significant?
Then I'm out.
glta.
-Chaka

[Renee]

M Pharmaceutical Inc. changed to Callitas Health Inc. and a one for 10 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[Chaka]

You're so lucky good sir.
Still, I'm very happy with what I have ATM.
Let's make some NOISE LONGS!
Hee:)

[Chaka]

Indeed..
GLAD I was able to BUY 50K MPHMF.
I was HOPING maybe another 2 weeks of QUIETNESS.
But, it looks like BLUES SKY UP AHEAD LONGS!
I join late to the party a little bit LATE.
But, no complain from me that's for sure.
gltua:)

[cdh11]

Huge partner coming fellas

[cdh11]

EXPLOSIVE NEWS COMNG $800millon sales drug!!

[cdh11]

IM LOADING HEAVY JV coming

[Crytek89]

boom, its starting

[Chaka]

Average VOLUME for 30 days: 20K
TODAY: VOLUMES 400K.
glta:)

[Chaka]

I hope so!
Looking forward next month for sure.
Hopefully the launching will HAPPEN.
glta:)

[Crytek89]

It's a 10 bagger no less

[Crytek89]

There is no connection to MCIC... QUIT pumping.

M Pharma biought 40 J which is reformulated Orlistat.. Basically GSK Glaxosmith Klein makes Orlistat and M pharama is reformulating Orlistat.. HUGE Opportunity.

Also They have Extrinsa... Female Sexual Dysfunction.. I'm sure you know Alli which was bought by Sprott Pharamceuticals.

Your welcome lol do you DD and your future self will thank you

[Crytek89]

Not a problem! Unfortunately the american side is quite iliquid. I know alot of people buying up on the CAD side like crazy. As am I. They have alot in the pipeline and FDA news coming within 60 days and they have a product launch coming in mid September. They are also starting a marketing blitz soon so look out for that!

Big things coming and thats why I've been buying CAD side becasue of illquid on US OTC. Either way good stuff coming and on top they just launched their new website.

[gorbec1]

No, I bring it up and no one talks about it but if you look at how this came alive and after mcic says migraine Pat. and rumor had it more in Pool. mcic they worked on diabetes too but we will see. maybe nothing funny they want to release something come Sept. Then mcic web site said about the time (thanks for shareholders patient more news coming new 15 bil dollar market) this company was working on buying the new one and now say they will release info in sept I expect mcic will too

[Chaka]

I did not know there's a connection between MPHMF & MCIC.
Granted an article was written about is not a sure thing..
But, nontheless, that's very interesting.
Btw..
Has this TOPIC still discuss over MCIC?
Just wondering.
I may have to dig deeper in my DD.
I intend to load before September launch date.
glta:)

[gorbec1]

Well, I came here because a few years ago the was an article saying mcic was trying to buy this company, When nothing was happening. Then this stock started doing things and coming alive, right after mcic puts out that it had new pat. on migraines.

Also, mcic use to do something with diabete sand they are looking to do something soon . I bet Sept. is just like this one and we hear about mcic too. glty We may be partners, maybe not will see!

[gorbec1]

funny you mention that sept im with another company and im expecting things to star with them the other company had info they tryied to buy this company funny thing is this company came alive back when the other company put out they had new pat. on migraine

[Chaka]

Thanks for the UPDATE.
I was about to post a new NAME CHANGED in the AM.
But, you beat me to it!
...:)
Although, I'm very NEW here with MPHMF, but this company POTENTIAL PIPELINES definitely very impressive.
They're TARGETING women's wellness, fitness, fertility, and sexual disorder?
Wow..
I intend to load before the September LAUNCH BEGIN.
---------------
Q..
Your thoughts on MPHMF NEXT 6 MONTHS PPS?
IYO.

[gorbec1]

name change

[gorbec1]

https://www.pharmpro.com/news/2017/08/m-pharmaceutical-usa-changes-name-callitas-therapeutics

[gorbec1]

looking forward to seeing this unfold glta

[gorbec1]

i did see they bought did something with diabetic equip any one know about that

[gorbec1]

i noticed this started coming alive again about 2 years ago or so am i right

[gorbec1]

nice do you know what the float is thank you in advance

[Chaka]

Nice!
Thanks for the response.
I researched Gary background..( quite impressive )
This company has big potential & is definitely a LONG-PLAY.
Looking to ACCUMULATE starting this month going forward.
glta:)

[Crytek89]

It's ready to take off ! I won't be surprised this hits 50 cents very soon. They are launching ToConcieve in September and have an FDA Submission for Extrinsa! Female Sexual Dysfunction is a big market. Alli was bought by Sprott Pharmaceuticals.

The CEO Gary Thmopson was the Vice President of Sales and Marketing for Cigna Health.. It trades at 174 dollars.. Yes dollars!!! This is not small meat and potatoes! Big Things coming! FDA News will pop the lid of this badboy !

[Chaka]

" the Company is scheduled to launch their FDA cleared fertility product branded as ToConceive in September of 2017. "
-----------------------------------------------------
Am I hearing this CORRECTLY?
FDA CLEARED fertility product ToCONCEIVE is launching in September 2017?
This company is ready to start generating revenues going forward?
This definitely got my ATTENTION Dumbof.
Hee:)

[Campeese]

$500 MILLION EXPECTED REVENUES!!

http://www.stockhouse.com/news/press-releases/2017/07/14/m-pharmaceutical-inc-provides-further-information-on-reformulated-orlistat-and

[dumbof]

M Pharmaceutical Inc. Provides Strategic Report to Shareholders Highlighting Acquisitions and Product Development

https://www.stockwatch.com/News/Item.aspx?bid=U-fsx00017659-U%3aMPHMF-20170713&symbol=MPHMF®ion=U

https://www.stockwatch.com/Quote/Detail.aspx?symbol=MPHMF®ion=U

[dumbof]

read:

https://www.stockwatch.com/News/Item.aspx?bid=U-fsx00017424-U%3aMPHMF-20170630&symbol=MPHMF®ion=U

ww.stockwatch.com/News/Item.aspx?bid=U-fsx00017472-U%3aMPHMF-20170705&symbol=MPHMF®ion=U

[Crytek89]

I deffinetly see alot of volume come the commercialization of their product for infertilaty which is FDA approved. Should be a great catalyst with others in the pipe